Generic Name and Formulations:
Trivalent poliovirus vaccine; inactivated; whole virus grown in monkey kidney cells; IM or SC inj.
Sanofi Pasteur, Inc.
Indications for IPOL:
Poliomyelitis immunization (virus Types 1, 2, and 3).
Inject IM or SC in deltoid area. Each dose is 0.5mL. Previously unvaccinated: Two doses at a 1–2 month interval and a third dose 6–12 months later. Incompletely vaccinated: give 1–2 doses to complete series. Completely vaccinated: may give booster dose.
Inject IM or SC in midlateral thigh. Each dose is 0.5mL. Under 6 wks: not recommended. Full IPV schedule: One dose at 2 months, 4 months, 6–18 months, and 4–6 years of age. Sequential schedule with oral polio vaccine (OPV) (do not use OPV for immunocompromised patients or patients with immunocompromised household contacts): One dose of IPOL at 2 months and at 4 months of age, then 1 dose of OPV at 12–18 months and 1 dose of OPV at 4–6 years of age.
Hypersensitivity to neomycin, streptomycin, or polymyxin B. May defer in acute febrile illness.
Have epinephrine inj (1:1000) available. Immunodeficiency. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressants: may get suboptimal response.
Local irritation, fever, sleepiness, fussiness, decreased appetite.
Syringe 0.5mL (w. needle)—1, 10; Multidose vial (10 doses)—1
Clinical Pain Advisor Articles
- History of Migraine May Be Associated With Higher Risk for Cochlear Disorders
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Symptom Severity, Sensory Sensitivity May Indicate Pain Centralization in Chronic Overlapping Pain Conditions
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness